Clinical study with recombinant interferon gamma versus interferon alpha-2c in patients with condylomata acuminata.
A multi-centre, randomized, open-label trial was conducted to evaluate the safety and efficacy of recombinant interferon (rIFN) alpha-2c versus rIFN gamma in patients with recurrent or persistent condylomata acuminata (CA). Thirty-three such patients were treated either with 6 micrograms rIFN alpha-2c or with 0.1 mg rIFN gamma (both equivalent to 2 x 10E6 IU), single dose, subcutaneously 3 times a week for 6 weeks. In case of no complete clearance at week 10, a second course of treatment with the other type of rIFN was given. There was no significant difference in the complete clearance proportions at week 10 between the two treatment groups (3/16 vs 6/17). No relapses occurred in these patients during the 16 weeks' follow-up. Further clearances during the follow-up resulted in a total complete clearance proportion of 14/33 at the end of study. The treatment was well tolerated. Repeated interferon therapy has its place in treating persistent or recurrent condylomas.
Reichel
R P
RP
1st Department of Gynaecology and Obstetrics, University of Vienna, Austria.
Fitz
R
R
Neumann
R
R
Pohl-Markl
H
H
Pichler
E
E
Hoffer
Z
Z
Budiman
R
R
D000293:Adolescent; D000328:Adult; D003218:Condylomata Acuminata / Q000628:therapy*; D005260:Female; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects / Q000627:therapeutic use*; D007371:Interferon-gamma / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D014565:Urogenital Neoplasms / Q000628:therapy*
D007370:Interferon Type I; D011994:Recombinant Proteins; D007371:Interferon-gamma